CYCC logo

Cyclacel Pharmaceuticals (CYCC)

Profile

Full Name

Cyclacel Pharmaceuticals, Inc.

Ticker Symbol

CYCC

Exchange

NASDAQ

Sector

Healthcare

Industry

Biotechnology

Country

Malaysia

IPO

March 16, 2004

Indexes

Not included

Website

http://www.cyclacel.com

Employees

12

Key Details

Price

$0.24(+4.30%)

Market cap

Last Dividend

-

TTM Dividend yield

-

Annual revenue

$43.00K(-89.76% YoY)

Annual EPS

-$2.09(+92.19% YoY)

PE ratio

-

Next earnings date

May 14, 2025

Next ex-dividend date

N/A

Next split date

N/A

Price

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Current Price

$0.24
CYCC price is $0.24

30-Day Relative Volume

1.06
CYCC 30-day relative volume is 1.06

Price Performance

Price Today change

+4.3%
CYCC price is up +4.3% today

Price YTD change

-36.87%
CYCC price is down -36.87% since January 1st

Price 1-year change

-85.63%
CYCC price is down -85.63% year-on-year

Price 3-year change

-99.22%
CYCC price is down -99.22% over the past 3 years

Price Range

Price All-time high

$239400.00
CYCC price is currently -100.00% below its historical high of $239400.00

Price 3-year low

$0.17
CYCC price is currently +41.12% above its 3-year low

Capitalization

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Market cap

Market cap

$49.74M
CYCC market capitalization is $49.74 million

Market cap 3-year change

+142.8%
CYCC market capitalization is up +142.8% over the past 3 years

Market cap All-time high

$179.42M
CYCC market capitalization is currently -72.28% below its historical high of $179.42 million

Market cap sector rank

38.4%
CYCC market capitalization is higher than 38.4% of companies in Healthcare sector

Shares Outstanding

Shares Outstanding 1-Year Change

+15627.56%
CYCC shares outstanding is up +15627.56% year-on-year

Shares Outstanding 3-Year Change

+31022.25%
CYCC shares outstanding is up +31022.25% over the past 3 years

Technical Indicators

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Beta

0.28
CYCC beta is 0.28

200-day SMA

$0.74
CYCC price is currently -67.46% below its 200-day simple moving average

50-day SMA

$0.30
CYCC price is currently -20.30% below its 50-day simple moving average

RSI

40.14
CYCC 14-day relative strength index is 40.14

Volume

1.06
CYCC 30-day relative volume is 1.06

ATR

$0.03
CYCC average true range is $0.03

10-day Historical Volatility

136.19%
CYCC 10-day historical volatility is 136.19%

Dividend

Income Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Revenue

$43.00K
CYCC annual revenue is $43.00 thousand

Revenue Analysts estimate

$100.00K
CYCC annual revenue is currently -57.00% lower than the consensus analysts' forecast

Revenue 1-year change

-89.76%
CYCC annual revenue is down -89.76% year-on-year

Revenue Sector rank

4.13%
CYCC annual revenue is higher than 4.13% of companies in Healthcare sector

EPS

EPS

-$2.09
CYCC annual earnings per share is -$2.09

EPS Analysts estimate

-$1.18
CYCC annual earnings per share is currently +77.12% higher than the consensus analysts' forecast

EPS 1-year change

+92.19%
CYCC annual earnings per share is up +92.19% year-on-year

EPS Sector rank

37.78%
CYCC annual earnings per share is higher than 37.78% of companies in Healthcare sector

Profit

Gross profit

-
CYCC annual gross profit value is unknown

Gross margin

-
CYCC annual gross profit margin value is unknown

Operating profit

-$12.00M
CYCC annual operating income is -$12.00 million

Operating margin

-27.92K%
CYCC annual operating profit margin is -27.92 thousand%

Net income

-$11.21M
CYCC annual net profit is -$11.21 million

Net margin

-26.07K%
CYCC annual net profit margin is -26.07 thousand%

Expenses

Total expenses

$12.05M
CYCC annual total expenses is $12.05 million

Operating expenses

$12.05M
CYCC annual total operating expenses is $12.05 million

Cost of goods sold

-
CYCC annual cost of goods sold value is unknown

Selling, general & administrative expenses

$5.39M
CYCC annual SGA is $5.39 million

Depreciation and amortization

$6000.00
CYCC annual depreciation & amortization is $6000.00

Interest expense

-
CYCC annual interest expense value is unknown

Income tax

-$782.00K
CYCC annual income tax is -$782.00 thousand

EBIT & EBITDA

EBIT

-$12.00M
CYCC annual earnings before interest & taxes is -$12.00 million

EBITDA

-$12.00M
CYCC annual EBITDA is -$12.00 million

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Total assets

$4.09M
CYCC annual total assets is $4.09 million

Non current assets

$419.00K
CYCC annual long term assets is $419.00 thousand

Current assets

$3.67M
CYCC annual total current assets is $3.67 million

Cash and cash equivalents

$3.14M
CYCC annual cash & cash equivalents is $3.14 million

Accounts receivable

-
CYCC annual accounts receivable value is unknown

Inventory

-
CYCC annual inventory value is unknown

Liabilities

Total liabilities

$6.27M
CYCC annual total liabilities is $6.27 million

Long term liabilities

$0.00
CYCC annual total long term liabilities is $0.00

Current liabilities

$6.27M
CYCC annual total current liabilities is $6.27 million

Accounts payable

$4.60M
CYCC annual accounts payable is $4.60 million

Debt

Total debt

$0.00
CYCC annual total debt is $0.00

Total debt 1-year change

-100%
CYCC annual total debt is down -100% year-on-year

Long term debt

$0.00
CYCC annual long term debt is $0.00

Short term debt

-
CYCC annual short term debt value is unknown

Equity & Capital

Shareholders equity

-$2.17M
CYCC annual stockholders equity is -$2.17 million

Book value

-$2.17M
CYCC annual book value is -$2.17 million

Retained earnings

-$439.49M
CYCC annual retained earnings is -$439.49 million

Working capital

-$2.59M
CYCC annual working capital is -$2.59 million

Cash Flow Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Cash from operations

-$7.99M
CYCC annual cash flow from operations is -$7.99 million

Cash from operations 1-year change

+50.41%
CYCC annual cash flow from operations is up +50.41% year-on-year

Cash from investing

$0.00
CYCC annual cash flow from investing activities is $0.00

Cash from investing 1-year change

+100%
CYCC annual cash flow from investing activities is up +100% year-on-year

Cash from financing

$7.82M
CYCC annual cash flow from financing activities is $7.82 million

Cash from financing 1-year change

+822.41%
CYCC annual cash flow from financing activities is up +822.41% year-on-year

CAPEX

CAPEX

-
CYCC annual capital expenditures value is unknown

CAPEX 1-year change

-
CYCC annual capital expenditures 1-year change is unknown

Free Cash Flow

Free cash flow

-$7.99M
CYCC annual free cash flow is -$7.99 million

Free cash flow 1-year change

+50.43%
CYCC annual free cash flow is up +50.43% year-on-year

Profitability Ratios

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Margins

Gross margin

-
CYCC annual gross profit margin value is unknown

Operating margin

-27.92K%
CYCC annual operating profit margin is -27.92 thousand%

Net margin

-26.07K%
CYCC annual net profit margin is -26.07 thousand%

ROA & ROE

ROA

-173.84%
CYCC annual return on assets is -173.84%

ROE

515.73%
CYCC annual return on equity is 515.73%

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PE ratio

-
CYCC price to earnings ratio value is unknown

PE ratio Sector rank

-
CYCC price to earnings ratio is unknown

PB Ratio

PB ratio

-22.88
CYCC price to book ratio is -22.88

PB ratio Sector rank

1.65%
CYCC price to book ratio is higher than 1.65% of companies in Healthcare sector

PS Ratio

PS ratio

-
CYCC price to sales ratio value is unknown

PS ratio Sector rank

-
CYCC price to sales ratio is unknown

Enterprise value

Enterprise value

$46.60M
CYCC enterprise value is $46.60 million

Enterprise value Sector rank

40.78%
CYCC enterprise value is higher than 40.78% of companies in Healthcare sector

EV/EBITDA

EV/EBITDA

-3.87
CYCC EV/EBITDA is -3.87

EV/EBITDA Sector rank

22.02%
CYCC EV/EBITDA is higher than 22.02% of companies in Healthcare sector

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Current ratio

0.59
CYCC annual current ratio is 0.59

Quick ratio

-
CYCC annual quick ratio value is unknown

Leverage

Debt to equity

0.00
CYCC annual debt to equity ratio is 0.00

Interest coverage ratio

-
CYCC annual interest coverage ratio value is unknown

Risk & Stability

Piotroski F-Score

-
CYCC piotroski f-score value is unknown

Altman Z-Score

-155.96
CYCC altman z-score is -155.96

Analyst ratings

Recent major analysts updates

May 3, 24 Roth MKM
Buy
Dec 19, 23 Roth MKM
Buy
Dec 19, 23 Brookline Capital
Hold
May 25, 23 Oppenheimer
Outperform
Mar 7, 23 Oppenheimer
Outperform
Apr 30, 21 Oppenheimer
Outperform
Nov 25, 20 Roth Capital
Buy
Nov 25, 20 JMP Securities
Market Outperform
Nov 25, 20 H.C. Wainwright
Buy
Sep 5, 18 Roth Capital
Buy

Institutional Ownership

Similar stocks

VNRX logo
VolitionRx Limited (VNRX)
ICCC logo
ImmuCell (ICCC)
VTVT logo
vTv Therapeutics (VTVT)
STRO logo
Sutro Biopharma (STRO)
RPTX logo
Repare Therapeutics (RPTX)
BYSI logo
BeyondSpring (BYSI)
IMMX logo
Immix Biopharma (IMMX)
PRE logo
Prenetics Global Limited (PRE)
ATHE logo
Alterity Therapeutics Limited (ATHE)
  • What is the ticker symbol for Cyclacel Pharmaceuticals?
  • Does Cyclacel Pharmaceuticals pay dividends?
  • What sector is Cyclacel Pharmaceuticals in?
  • What industry is Cyclacel Pharmaceuticals in?
  • What country is Cyclacel Pharmaceuticals based in?
  • When did Cyclacel Pharmaceuticals go public?
  • Is Cyclacel Pharmaceuticals in the S&P 500?
  • Is Cyclacel Pharmaceuticals in the NASDAQ 100?
  • Is Cyclacel Pharmaceuticals in the Dow Jones?
  • When was Cyclacel Pharmaceuticals's last earnings report?
  • When does Cyclacel Pharmaceuticals report earnings?
  • Should I buy Cyclacel Pharmaceuticals stock now?

What is the ticker symbol for Cyclacel Pharmaceuticals?

The ticker symbol for Cyclacel Pharmaceuticals is NASDAQ:CYCC

Does Cyclacel Pharmaceuticals pay dividends?

No, Cyclacel Pharmaceuticals does not pay dividends

What sector is Cyclacel Pharmaceuticals in?

Cyclacel Pharmaceuticals is in the Healthcare sector

What industry is Cyclacel Pharmaceuticals in?

Cyclacel Pharmaceuticals is in the Biotechnology industry

What country is Cyclacel Pharmaceuticals based in?

Cyclacel Pharmaceuticals is headquartered in Malaysia

When did Cyclacel Pharmaceuticals go public?

Cyclacel Pharmaceuticals's initial public offering (IPO) was on March 16, 2004

Is Cyclacel Pharmaceuticals in the S&P 500?

No, Cyclacel Pharmaceuticals is not included in the S&P 500 index

Is Cyclacel Pharmaceuticals in the NASDAQ 100?

No, Cyclacel Pharmaceuticals is not included in the NASDAQ 100 index

Is Cyclacel Pharmaceuticals in the Dow Jones?

No, Cyclacel Pharmaceuticals is not included in the Dow Jones index

When was Cyclacel Pharmaceuticals's last earnings report?

Cyclacel Pharmaceuticals's most recent earnings report was on Apr 2, 2025

When does Cyclacel Pharmaceuticals report earnings?

The next expected earnings date for Cyclacel Pharmaceuticals is May 14, 2025

Should I buy Cyclacel Pharmaceuticals stock now?

As of today, analysts generally recommend a 'Hold' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions
On this page